(Q51740287)

English

Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder.

scientific article published on 7 December 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/21136299

Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/21136299

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

quality of life

1 reference

based on heuristic

inferred from title

conduct disorder

0 references

1 reference

based on heuristic

inferred from title

Ulrike Ravens-Sieberer

8

object named as

Ulrike Ravens-Sieberer

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

Monika Bullinger

7

object named as

Monika Bullinger

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

author name string

Peter M Wehmeier

1

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/21136299

Alexander Schacht

2

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/21136299

Ralf W Dittmann

3

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/21136299

Karin Helsberg

4

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/21136299

Christian Schneider-Fresenius

5

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/21136299

Martin Lehmann

6

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/21136299

publication date

7 December 2010

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/21136299

Quality of Life Research

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/21136299

20

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/21136299

5

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/21136299

691-702

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/21136299

https://scigraph.springernature.com/pub.10.1007/s11136-010-9803-5

0 references

Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Families of children with attention-deficit/hyperactivity disorder: review and recommendations for future research

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Attention-deficit/hyperactivity disorder and social dysfunctioning

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Factors related to health-related quality of life (HRQoL) among children with ADHD in Europe at entry into treatment

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Health-related quality of life of children and adolescents with mental disorders.

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

ADHD comorbidity findings from the MTA study: comparing comorbid subgroups

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Affective valence and arousal in ADHD and normal boys during a startle habituation experiment.

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD.

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, mul

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

[Methodological challenges and potentials of health-related quality of life evaluation in children with chronic health conditions under medical health care].

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Psychometric properties of the KINDL-R questionnaire: results of the BELLA study.

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Assessing health-related quality of life in chronically ill children with the German KINDL: first psychometric and content analytical results.

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

International adoption: a four-year-old child with unusual behaviors adopted at six months of age.

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Resolving emotional conflict: a role for the rostral anterior cingulate cortex in modulating activity in the amygdala

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

The cognitive control of emotion

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Self-esteem in adolescent patients with attention-deficit/hyperactivity disorder during open-label atomoxetine treatment: psychometric evaluation of the Rosenberg Self-Esteem Scale and clinical findings

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Measuring quality of life in children with attention-deficit/hyperactivity disorder and their families: development and evaluation of a new tool.

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

Attention-deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1007%2FS11136-010-9803-5

21 January 2018

The testing and validation of the German version of the impact on family scale in families with children with disabilities

1 reference

https://pubmed.ncbi.nlm.nih.gov/21136299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/21136299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Family Strain Index (FSI). Reliability, validity, and factor structure of a brief questionnaire for families of children with ADHD

1 reference

https://pubmed.ncbi.nlm.nih.gov/21136299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD

1 reference

https://pubmed.ncbi.nlm.nih.gov/21136299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence of ADHD and comorbid disorders among elementary school children screened for disruptive behavior

1 reference

https://pubmed.ncbi.nlm.nih.gov/21136299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes?

1 reference

https://pubmed.ncbi.nlm.nih.gov/21136299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Emotional and behavioral difficulties and impairments in everyday functioning among children with a history of attention-deficit/hyperactivity disorder.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21136299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of comorbid oppositional or conduct problems on attention-deficit hyperactivity disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/21136299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of comorbidity in conduct disorder with attention-deficit hyperactivity disorder (ADHD).

1 reference

https://pubmed.ncbi.nlm.nih.gov/21136299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measuring subjective health in children and adolescents: results of the European KIDSCREEN/DISABKIDS Project

1 reference

https://pubmed.ncbi.nlm.nih.gov/21136299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/21136299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Co-existing psychiatric problems in ADHD in the ADORE cohort.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21136299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact on family scale revisited: further psychometric data

1 reference

https://pubmed.ncbi.nlm.nih.gov/21136299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Validity of the revised Impact on Family (IOF) scale

1 reference

https://pubmed.ncbi.nlm.nih.gov/21136299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21136299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The development of an impact-on-family scale: preliminary findings.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21136299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21136299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11136-010-9803-5

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/21136299

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/21136299

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51740287&oldid=1510741819"